Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
- None.
- None.
Insights
The reported preliminary and unaudited net sales figures for Glaukos Corporation indicate a significant financial milestone for the company. The reported $81 million for Q4 and $313 million for the full year suggest a robust sales performance. Investors should note the company's ability to generate revenue, which is a critical factor for assessing the company's growth trajectory and market position. Moreover, the reaffirmation of the 2024 net sales guidance range of $350 million to $360 million provides a forward-looking statement that could influence investor expectations and market sentiment. It's important to compare these figures against industry growth rates and competitors' performance to gauge market share dynamics and potential future earnings.
Analyzing the ophthalmic medical technology sector, Glaukos Corporation's performance can be indicative of the sector's overall health. The demand for treatments in glaucoma, corneal disorders and retinal diseases is driven by an aging population and increased prevalence of these conditions. The preliminary sales data suggests that Glaukos is maintaining a competitive edge in the market. However, stakeholders should consider the potential impact of R&D investments, regulatory changes and reimbursement policies on future sales. Additionally, the company's ability to maintain or grow its market share amidst competition and technological advancements is pivotal for long-term success.
Glaukos Corporation's focus on novel therapies is a strategic advantage in the medical technology industry. The company's performance, as suggested by the preliminary sales figures, reflects the successful adoption and penetration of its products in the market. It's essential to evaluate the company's product pipeline and innovation capabilities, as these are critical drivers for sustained growth in the medical technology field. The reaffirmed sales guidance also indicates management's confidence in the company's strategic direction and operational execution. Stakeholders should assess the company's clinical development progress and any potential regulatory milestones that could influence future sales and market share.
Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of
In addition, the company reaffirms its 2024 net sales guidance range of
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which we are able to obtain regulatory approval for investigational products, our ability to successfully commercialize and generate sales of our products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products, our ability to compete successfully in the pharmaceutical industry, which is highly competitive and rapidly changing, our compliance with federal and state laws and regulations for the approval, sale and marketing of our products and our manufacturing processes, the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes, and the continued efficacy and safety profile of our products as reported in the pivotal trials and other clinical studies. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which was filed with the Securities and Exchange Commission (SEC) on November 1, 2023. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109502532/en/
Investor Contact:
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
What did Glaukos Corporation announce regarding its net sales?
What is the ticker symbol for Glaukos Corporation?
What is the focus of Glaukos Corporation's medical technology and pharmaceutical products?
When are the net sales figures expected to be audited?
What is the 2024 net sales guidance range reaffirmed by Glaukos Corporation?
